Posted by Michael Wonder on 26 Jul 2022
European Commission approves Rinvoq (upadacitinib) for the treatment of adults with moderate to severe ulcerative colitis
26 July 2022 - The approval is based on the results of three Phase 3 studies: two for induction and one for maintenance.
AbbVie today announced the European Commission approved Rinvoq (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
